View Future GrowthSCHOTT Pharma KGaA 過去の業績過去 基準チェック /26SCHOTT Pharma KGaAは、平均年間5.2%の収益成長を遂げていますが、 Life Sciences業界の収益は、年間 成長しています。収益は、平均年間4.4% 4.6%収益成長率で 成長しています。 SCHOTT Pharma KGaAの自己資本利益率は15.2%であり、純利益率は14.4%です。主要情報5.16%収益成長率5.17%EPS成長率Life Sciences 業界の成長26.83%収益成長率4.58%株主資本利益率15.18%ネット・マージン14.41%次回の業績アップデート12 Aug 2026最近の業績更新Reported Earnings • May 14Second quarter 2026 earnings released: EPS: €0.21 (vs €0.25 in 2Q 2025)Second quarter 2026 results: EPS: €0.21 (down from €0.25 in 2Q 2025). Revenue: €247.9m (down 1.5% from 2Q 2025). Net income: €31.0m (down 19% from 2Q 2025). Profit margin: 13% (down from 15% in 2Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.Reported Earnings • Dec 14Full year 2025 earnings released: EPS: €0.97 (vs €0.99 in FY 2024)Full year 2025 results: EPS: €0.97 (down from €0.99 in FY 2024). Revenue: €986.2m (up 3.0% from FY 2024). Net income: €146.5m (down 2.2% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Europe.お知らせ • Dec 06SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025お知らせ • Oct 09SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026お知らせ • Aug 19+ 2 more updatesSCHOTT Pharma AG & Co. KGaA to Report Q3, 2026 Results on Aug 12, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report Q3, 2026 results on Aug 12, 2026お知らせ • Nov 16SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 10, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results on Dec 10, 2025すべての更新を表示Recent updatesBuy Or Sell Opportunity • Jun 08Now 20% undervaluedOver the last 90 days, the stock has risen 26% to €17.36. The fair value is estimated to be €21.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.6% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 6.1% per annum. Earnings are also forecast to grow by 9.4% per annum over the same time period.Reported Earnings • May 14Second quarter 2026 earnings released: EPS: €0.21 (vs €0.25 in 2Q 2025)Second quarter 2026 results: EPS: €0.21 (down from €0.25 in 2Q 2025). Revenue: €247.9m (down 1.5% from 2Q 2025). Net income: €31.0m (down 19% from 2Q 2025). Profit margin: 13% (down from 15% in 2Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.お知らせ • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.New Risk • Jan 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 6.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.お知らせ • Dec 22SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time.Reported Earnings • Dec 14Full year 2025 earnings released: EPS: €0.97 (vs €0.99 in FY 2024)Full year 2025 results: EPS: €0.97 (down from €0.99 in FY 2024). Revenue: €986.2m (up 3.0% from FY 2024). Net income: €146.5m (down 2.2% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Europe.お知らせ • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.Valuation Update With 7 Day Price Move • Dec 12Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €15.10, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €29.64 per share.New Risk • Dec 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Dec 06SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025お知らせ • Oct 09SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026お知らせ • Aug 19+ 2 more updatesSCHOTT Pharma AG & Co. KGaA to Report Q3, 2026 Results on Aug 12, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report Q3, 2026 results on Aug 12, 2026お知らせ • Jun 13SCHOTT Pharma Management AG Announces CFO ChangesThe Supervisory Board of SCHOTT Pharma Management AG has decided that CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden.お知らせ • Nov 16SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 10, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results on Dec 10, 2025収支内訳SCHOTT Pharma KGaA の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BIT:1SXP 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Mar 269911431312731 Dec 259951501322830 Sep 259861461312830 Jun 259771471292731 Mar 259741481282531 Dec 249561351262530 Sep 249571501252430 Jun 249491501262731 Mar 249161351252831 Dec 239061581242730 Sep 238991521232730 Jun 238731431232430 Sep 228211251112430 Sep 21649101922230 Sep 20584779024質の高い収益: 1SXPは 高品質の収益 を持っています。利益率の向上: 1SXPの現在の純利益率 (14.4%)は、昨年(15.2%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 1SXPの収益は過去 5 年間で年間5.2%増加しました。成長の加速: 1SXPは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: 1SXPは過去 1 年間で収益成長率がマイナス ( -3.5% ) となったため、 Life Sciences業界平均 ( 8.5% ) と比較することが困難です。株主資本利益率高いROE: 1SXPの 自己資本利益率 ( 15.2% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/02 09:18終値2026/07/02 00:00収益2026/03/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SCHOTT Pharma AG & Co. KGaA 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23 アナリスト機関Gaurav JainBarclaysPallav MittalBarclaysJonathon UnwinBarclays20 その他のアナリストを表示
Reported Earnings • May 14Second quarter 2026 earnings released: EPS: €0.21 (vs €0.25 in 2Q 2025)Second quarter 2026 results: EPS: €0.21 (down from €0.25 in 2Q 2025). Revenue: €247.9m (down 1.5% from 2Q 2025). Net income: €31.0m (down 19% from 2Q 2025). Profit margin: 13% (down from 15% in 2Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
Reported Earnings • Dec 14Full year 2025 earnings released: EPS: €0.97 (vs €0.99 in FY 2024)Full year 2025 results: EPS: €0.97 (down from €0.99 in FY 2024). Revenue: €986.2m (up 3.0% from FY 2024). Net income: €146.5m (down 2.2% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Europe.
お知らせ • Dec 06SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025
お知らせ • Oct 09SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026
お知らせ • Aug 19+ 2 more updatesSCHOTT Pharma AG & Co. KGaA to Report Q3, 2026 Results on Aug 12, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report Q3, 2026 results on Aug 12, 2026
お知らせ • Nov 16SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 10, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results on Dec 10, 2025
Buy Or Sell Opportunity • Jun 08Now 20% undervaluedOver the last 90 days, the stock has risen 26% to €17.36. The fair value is estimated to be €21.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.6% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 6.1% per annum. Earnings are also forecast to grow by 9.4% per annum over the same time period.
Reported Earnings • May 14Second quarter 2026 earnings released: EPS: €0.21 (vs €0.25 in 2Q 2025)Second quarter 2026 results: EPS: €0.21 (down from €0.25 in 2Q 2025). Revenue: €247.9m (down 1.5% from 2Q 2025). Net income: €31.0m (down 19% from 2Q 2025). Profit margin: 13% (down from 15% in 2Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
お知らせ • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.
New Risk • Jan 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 6.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
お知らせ • Dec 22SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time.
Reported Earnings • Dec 14Full year 2025 earnings released: EPS: €0.97 (vs €0.99 in FY 2024)Full year 2025 results: EPS: €0.97 (down from €0.99 in FY 2024). Revenue: €986.2m (up 3.0% from FY 2024). Net income: €146.5m (down 2.2% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Europe.
お知らせ • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €15.10, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €29.64 per share.
New Risk • Dec 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Dec 06SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025
お知らせ • Oct 09SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026
お知らせ • Aug 19+ 2 more updatesSCHOTT Pharma AG & Co. KGaA to Report Q3, 2026 Results on Aug 12, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report Q3, 2026 results on Aug 12, 2026
お知らせ • Jun 13SCHOTT Pharma Management AG Announces CFO ChangesThe Supervisory Board of SCHOTT Pharma Management AG has decided that CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden.
お知らせ • Nov 16SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 10, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results on Dec 10, 2025